Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study



Dickinson, Laura ORCID: 0000-0001-5557-9396, Amin, Janaki, Else, Laura, Boffito, Marta, Egan, Deirdre, Owen, Andrew ORCID: 0000-0002-9819-7651, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David, Orrell, Catherine, Clarke, Amanda
et al (show 6 more authors) (2016) Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55 (7). pp. 861-873.

[thumbnail of Dickinson_E1_96wk_CPK_revision1_clean.docx] Text
Dickinson_E1_96wk_CPK_revision1_clean.docx - Author Accepted Manuscript

Download (186kB)

Abstract

<h4>Background</h4>ENCORE1 demonstrated non-inferiority of daily efavirenz 400 mg (EFV400) versus 600 mg (EFV600) to 96 weeks in treatment-naïve, HIV-infected adults but concerns regarding lower EFV400 concentrations remained. Therefore, relationships between EFV pharmacokinetics (PK) and key genetic polymorphisms with 96-week efficacy and safety were investigated.<h4>Methods</h4>Relationships between EFV PK parameters and single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) with plasma HIV-RNA (pVL) <200 copies/mL and EFV discontinuation and adverse events at 96 weeks were explored. Receiver operating characteristic curve analysis evaluated the predictability of mid-dose interval (C12) cutoffs and 96-week pVL.<h4>Results</h4>A total of 606 patients (32 % female; 37 % African, 33 % Asian; n = 311 EFV400, n = 295 EFV600) were included. EFV PK parameters, including C12, were not associated with pVL <200 copies/mL at 96 weeks (odds ratio [OR] 5.25, 95 % confidence interval [CI] 0.41-67.90, p = 0.204). Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15-0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02-2.09, p = 0.040; OR 2.31, 95 % CI 1.33-4.02, p = 0.003, respectively). Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19-5.43, p = 0.016). C12 between 0.47 and 0.76 mg/L provided sensitivity/specificity >90 % (100 %/92.3 to 98.9 %/92.3 %) for achieving pVL <200 copies/mL at 96 weeks.<h4>Conclusions</h4>A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed. Although a single threshold concentration associated with HIV suppression may be clinically useful, it was not viable for ENCORE1. Implementation of EFV400 would improve toxicity management whilst still maintaining good efficacy.

Item Type: Article
Uncontrolled Keywords: Humans, HIV Infections, Alkynes, Cyclopropanes, Benzoxazines, RNA, Viral, Anti-HIV Agents, Metabolic Clearance Rate, Area Under Curve, Double-Blind Method, Pharmacogenetics, Dose-Response Relationship, Drug, Genotype, Polymorphism, Single Nucleotide, Adolescent, Adult, Middle Aged, Female, Male, Young Adult, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Constitutive Androstane Receptor
Depositing User: Symplectic Admin
Date Deposited: 13 Jul 2018 15:06
Last Modified: 19 Jan 2023 07:34
DOI: 10.1007/s40262-015-0360-5
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3002215